seco-rapamycin-sodium

Description: Seco Rapamycin sodium (Secorapamycin A monosodium), the sodium salt of the ring-opened product of Rapamycin, is reported not to affect the mTOR function. Rapamycin (also known as Sirolimus), a natural macrocyclic lactone isolated from the bacterium Streptomyces hygroscopicus, is a specific and potent mTOR inhibitor with IC50 of ca.0.1 nM in HEK293 cells. Rapamycin was used as a kind of original antifungal antibiotic, but since it also demonstrated immunosuppressant properties, it is being used in the prevention of transplant rejection because of its immunosuppressive effect. It also exhibits activity against several transplantable tumors and slightly activity to inactive against leukemias. The immunosuppressive effect of Rapamycin is exerted by inhibiting the activation and proliferation of T cells. Rapamycin binds to FK-binding protein 12 (FKBP12) and forms the rapamycin-FKBP12 complex, which regulates an enzyme that plays an important role in the progression of the cell cycle.

References: J Pharmacol Exp Ther. 2002 Apr; 301(1):174-86.; J Antibiot (Tokyo). 1975 Oct; 28(10):727-32; Cancer Res. 2005 Apr 15; 65(8):3336-46.

Related CAS: 53123-88-9 (Rapamycin); 147438-27-5 (ring-opened product of Rapamycin); 221877-56-1 (prodrug of a rapamycin analog); Other related mTOR inhibitors: 83482-58-0 (Demethoxyrapamycin); 355428-84-1 (3HOI-BA-01); 5142-23-4 (3-Methyladenine); 57818-44-7 (ABTL0812); 944153-47-3 (SMER18)